Efficacy and Safety of Angiotensin Receptor Blockers in Pediatric Patients (Aged 6 to 18) with Hypertension: A Systematic Review

Authors

  • Sahar Bassiri Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Author
  • Elham Bakhtiari Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Author
  • Nafise Ghaffarian Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Author
  • Nasrin Moazzen Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Author
  • Yalda Ravanshad Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran Author
  • Anoush Azarfar Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Author

Abstract

Angiotensin receptor blockers (ARBs) are commonly prescribed in pediatric hypertension because of the fundamental role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertension. We, therefore, aimed to systematically review articles that investigated efficacy and safety of ARB agents in the pediatric population aged over six years. To do so, the databases of Web of Science, PubMed/MEDLINE, and Scopus were searched to conduct a systematic review by using the following keywords: (“angiotensin receptor blocker” OR “valsartan” OR “losartan”) AND (“pediatric” OR “children” OR “child”) AND (“high blood pressure” OR “hypertension”). Finally, 12 studies were included in our review, and we found that almost all of them supported the effectiveness and tolerability of different ARB agents. Candesartan cilexetil lowered blood pressure (BP), with a 9 mmHg decline in both systolic and diastolic BP, and proteinuria after four months of treatment. Valsartan and Losartan similarly were shown to be effective in lowering BP in a dose-dependent manner. Headache, dizziness, upper respiratory infection, and cough were the most reported side effects. However, almost all reviewed studies indicated that the safety profile was satisfactory. In conclusion, ARBs are beneficial and well-tolerated antihypertensive medications.

 

DOI: 10.52547/ijkd.7228

Downloads

Download data is not yet available.

Author Biographies

  • Sahar Bassiri, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
    Mashhad University of Medical Sciences, Mashhad, Iran
  • Nafise Ghaffarian, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
    Departments of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nasrin Moazzen, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
    Clinical Research Development Unit of Akbar hospital, Mashhad University of medical Sciences, Mashhad, Iran
  • Yalda Ravanshad, Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran
    Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
  • Anoush Azarfar, Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
    Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Downloads

Published

2023-06-20

Issue

Section

REVIEW | Kidney Diseases

How to Cite

Efficacy and Safety of Angiotensin Receptor Blockers in Pediatric Patients (Aged 6 to 18) with Hypertension: A Systematic Review. (2023). Iranian Journal of Kidney Diseases, 17(3), 117-125. https://www.ijkd.org/index.php/ijkd/article/view/7228

Most read articles by the same author(s)